Bahru Habtemariam

Bahru Habtemariam has a diverse and extensive work experience in the field of clinical pharmacology. Bahru is currently working as the Vice President of Clinical Pharmacology at Beam Therapeutics since October 2021. Prior to that, they held positions at Alnylam Pharmaceuticals, starting as a Director of Clinical Pharmacology in October 2017 and later promoted to Senior Director in January 2019.

Before joining the industry, Bahru Habtemariam worked at the FDA as a Team Leader of Clinical Pharmacology, where they ensured timely and high-quality review of NDA and IND submissions for regulatory decision making. Bahru also supervised and mentored reviewers, promoting career development and the use of quantitative clinical pharmacology. Bahru held this role from October 2015 to October 2017, following their position as a Senior Reviewer Clinical Pharmacology Reviewer from September 2008 to October 2015. During their time at the FDA, they conducted numerous reviews and assessments of clinical pharmacology aspects for various drugs.

Earlier in their career, Bahru Habtemariam worked as a Senior Scientist at Novartis from July 2006 to July 2008. Bahru also worked as a Fellow in Drug Development and Pharmacometrics at Cognigen from July 2004 to July 2006, where they performed PK/PD analysis and contributed to diabetes, asthma, HIV, and other infectious disease projects.

As a student researcher at the University of Maryland Baltimore CADD Center, Bahru Habtemariam worked on computer-aided drug design and molecular dynamic simulation projects. Bahru screened chemicals for receptor binding activity and conducted protein-protein and protein-DNA interaction simulations.

Overall, Bahru Habtemariam's work experience showcases their expertise in clinical pharmacology, drug development, regulatory affairs, and research.

Bahru Habtemariam earned a Doctor of Pharmacy (Pharm.D.) degree from the University of Maryland Baltimore from 2000 to 2004. Later in 2020 to 2021, they obtained a CORe Credential of Readiness from Harvard Business School Online.